SCHEMBL5045848

SCHEMBL5045848

CCCCCCSc1nc(C)cc(CN2CCC3CCCCC3C2)n1

nearest known ligand 0.37

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
GAA P10253 1/20 0.37
HTT P42858 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
CHRM1 P11229 7/20 0.36
GPR84 Q9NQS5 1/20 0.35
CHRM2 P08172 2/20 0.35
CHRM3 P20309 2/20 0.35
MEN1 O00255 1/20 0.32
KMT2A Q03164 1/20 0.32
GNAI3 P08754 1/20 0.32
GNAO1 P09471 1/20 0.32
GNAI1 P63096 1/20 0.32
ALDH1A1 P00352 1/20 0.32
CYP1A2 P05177 1/20 0.32
CYP3A4 P08684 1/20 0.32
ALOX12 P18054 1/20 0.32
CYP2C19 P33261 1/20 0.32
LMNA P02545 1/20 0.32
MAPT P10636 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5047621 0.85 GAA (0.38) GAAHTTSMN1; SMN2CHRM1GPR84
SCHEMBL5046056 0.83 HTT (0.37) GAAHTTSMN1; SMN2CHRM1GPR84
SCHEMBL5045981 0.83 ALDH1A1 (0.38) GAAHTTSMN1; SMN2GPR84MEN1
SCHEMBL5045769 0.83 SMN1; SMN2 (0.43) GAAHTTSMN1; SMN2GPR84MEN1
SCHEMBL5047449 0.83 SPHK1 (0.40) GAAHTTSMN1; SMN2GPR84MEN1
SCHEMBL5047348 0.82 SMN1; SMN2 (0.43) GAAHTTSMN1; SMN2GPR84MEN1
SCHEMBL5049973 0.82 SMN1; SMN2 (0.43) GAAHTTSMN1; SMN2GPR84MEN1
SCHEMBL5049995 0.80 SMN1; SMN2 (0.43) GAAHTTSMN1; SMN2GPR84ALDH1A1
SCHEMBL5047535 0.79 BCHE (0.51) GAASMN1; SMN2MEN1KMT2AALDH1A1
SCHEMBL5045838 0.79 SMN1; SMN2 (0.40) GAAHTTSMN1; SMN2GPR84ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7351700-B2 Aminomethylpyrimidines as allosteric enhancers of the GABAB receptors HOFFMANN-LA ROCHE INC. (US) 2008-04-01 US claimed
US-20050197337-A1 Aminomethylpyrimidines as allosteric enhancers of the GABAB receptors HOFFMANN-LA ROCHE INC. 2005-09-08 US claimed
US-7351700-B2 Aminomethylpyrimidines as allosteric enhancers of the GABAB receptors HOFFMANN-LA ROCHE INC. (US) 2008-04-01 US disclosed
EP-1725239-B1 4-(SULFANYL-PYRIMIDIN-4-YLMETHYL)-MORPHOLINE DERIVATIVES AND RELATED COMPOUNDS AS GABA RECEPTOR LIGANDS FOR THE TREATMENT OF ANXIETY, DEPRESSION AND EPILEPSY HOFFMANN LA ROCHE (CH) 2007-07-18 EP disclosed
US-20050197337-A1 Aminomethylpyrimidines as allosteric enhancers of the GABAB receptors HOFFMANN-LA ROCHE INC. 2005-09-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050197337-A1 Aminomethylpyrimidines as allosteric enhancers of the GABAB receptors CHRNA2, CNR2, GABRB2 GAA 1891/4885HTT 2596/4885SMN1; SMN2 98/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.